molmed

Investors

Notice of Offering with pre-emptive rights (in Italian)

Notice of Offering with pre-emptive rights (in Italian) ▾

Investors

Share capital increase: conclusion of the offer with pre-emptive rights Pdf

Share capital increase: conclusion of the offer with pre-emptive rights Pdf ▾

Investors

TK submission for Conditional Approval validated by EMA

TK submission for Conditional Approval validated by EMA ▾

Investors

MolMed TK therapy submitted for Conditional Marketing Authorisation in EU Pdf

MolMed TK therapy submitted for Conditional Marketing Authorisation in EU Pdf ▾

Investors

Share capital increase against payment with pre-emptive rights: errata corrige

Share capital increase against payment with pre-emptive rights: errata corrige ▾

Investors

Outcome of extraordinary Shareholders' Meeting and meeting of the Board of Directors

Outcome of extraordinary Shareholders' Meeting and meeting of the Board of Directors ▾

Investors

Update on the registration strategy for the gene therapy TK in Europe and in the United States

Update on the registration strategy for the gene therapy TK in Europe and in the United States ▾

Investors

MolMed Board of Directors calls for extraordinary Shareholders’ Meeting

MolMed Board of Directors calls for extraordinary Shareholders’ Meeting ▾

Investors

The European Patent Office grants MolMed a new patent on its gene therapy platform

The European Patent Office grants MolMed a new patent on its gene therapy platform ▾

Investors

Notice of filing of financial report at 30 september 2013

Notice of filing of financial report at 30 september 2013 ▾

Subscribe to

Subscribe to press releases

Dear Users, we would like to inform you that, as of 30 September, AGC Biologics S.p.A. (formerly MolMed S.p.A.) is no longer listed on the Milan Stock Exchange and has become part of the AGC Biologics Group. For any information on the company and the group, you are kindly invited to consult the websitewww.agcbio.com.
The contents present on this portal (www.molmed.com) are updated until the date of September 30, 2020 and will be available for the time frame foreseen by applicable regulations.
In addition, the "work with us" section is still active, while the contact details are no longer accessible.